Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Account Payables (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Change in Account Payables for 13 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 186.03% to -$1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 million, a 312.75% increase, with the full-year FY2025 number at $2.3 million, up 312.75% from a year prior.
  • Change in Account Payables was -$1.9 million for Q4 2025 at Niagen Bioscience, down from -$938000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.0 million in Q2 2025 to a low of -$2.3 million in Q1 2024.
  • A 5-year average of $99500.0 and a median of -$87500.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 229.26% in 2022, then soared 1379.61% in 2025.
  • Niagen Bioscience's Change in Account Payables stood at -$381000.0 in 2021, then soared by 246.98% to $560000.0 in 2022, then surged by 84.64% to $1.0 million in 2023, then soared by 118.76% to $2.3 million in 2024, then plummeted by 186.03% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Change in Account Payables are -$1.9 million (Q4 2025), -$938000.0 (Q3 2025), and $3.0 million (Q2 2025).